EEF1E1 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human Burkitt??s lymphoma B lymphocyte line Raji, designed to disrupt the EEF1E1 gene locus. This polyclonal format offers a heterogeneous pool of loss-of-function mutants that collectively ablate EEF1E1 expression, providing a robust model for studying p18 deficiency without single-cell cloning artifacts.
The Raji host cell line, originally derived from an EBV-positive Burkitt??s lymphoma patient, grows as a suspension lymphoblastoid culture and is extensively used in immunology and oncology due to its consistent growth and well-documented signaling pathways. Its rapid proliferation and EBV-driven immortalization provide a relevant B cell malignancy context for investigating the tumor-suppressive and translational roles of EEF1E1.
EEF1E1 encodes the p18 auxiliary factor, a core component of the multi-synthetase complex (MSC) that channels aminoacyl-tRNAs to the ribosome and serves as a guanine nucleotide exchange factor for eEF1A during translation elongation. Upon DNA damage, p18 translocates to the nucleus, where it interacts with ATM and ATR kinases to facilitate DNA repair and stabilize p53. This positions EEF1E1 at the intersection of mTORC1-driven protein synthesis (via p70S6K and eIF4E) and the ATM/ATR-p53-CHK2 genome surveillance pathway, with additional inputs from amino acid availability. Critical MSC partners include KARS, MARS, AIMP1, and AIMP2, which collectively coordinate translation with cellular stress responses.
In Raji B lymphocytes, EEF1E1 knockout disrupts these dual functions, enabling dissection of p18-dependent translation elongation control and DNA damage signaling in an EBV-positive lymphoma model. The polyclonal population can reveal how loss of EEF1E1 impacts proliferative capacity, genomic stability, and sensitivity to chemotherapeutics targeting the translational machinery or DNA repair pathways. Moreover, the polyclonal nature captures a range of mutational outcomes, offering a more physiologically diverse model than clonal isolates when interrogating population-level responses to genotoxic agents or mTOR inhibitors.
Typical experimental approaches include Western blot analysis of p18 and phospho-ATM, RT-qPCR for EEF1E1 mRNA, co-immunoprecipitation of MSC components, immunofluorescence for p18 nuclear translocation, flow cytometry for cell cycle and apoptosis profiling, and puromycin incorporation translation assays. Comet assays and ??H2AX immunostaining can quantify DNA damage accumulation. Genome-wide expression profiling by RNA-seq can further delineate pathways altered upon p18 ablation. For customized solutions or technical inquiries, please contact Ascent Research.
